Ehave, Inc. (OTC: EHVVF)

Ehave, Inc. is a digital therapeutics provider specializing in developing and implementing evidence-based interventions for mental and neurological health. Operating in the highly specialized digital health and mental wellness technology sector, the company focuses on creating a comprehensive mental health data platform. This platform integrates proprietary and third-party digital applications, aiming to optimize patient care by providing objective data insights to healthcare providers. The core activity involves delivering technology solutions designed for clinicians, patients, researchers, pharmaceutical companies, and payers.

The company generates revenue through multiple channels, combining software licensing with service provision. A significant stream of income derives from the use of its clinically validated digital assessment and rehabilitation software, MegaTeam and Ninja Reflex, designed for cognitive training. Furthermore, through its subsidiary, KetaDash, Ehave offers physical services, including Ketamine treatments and IV therapies like IV Drip Detox and Hydration Therapy. Ehave also generates revenue by providing contract services to researchers and developers, allowing them to enhance their own digital health applications using Ehave's expertise.

The company operates through the following segments:

• MegaTeam and Ninja Reflex: This segment provides clinically validated digital assessment and rehabilitation software. It features tasks built into an engaging video game environment, designed to address cognitive difficulties, particularly in Attention Deficit and Hyperactivity Disorder (ADHD).

• KetaDash: Operating through its wholly owned subsidiary, Ketadash, this segment offers a platform for medical practitioners to administer at-home healthcare services. It provides Ketamine treatments, IV infusions, and various therapies, including IV Drip Detox and Hangover Cures, for patients suffering from mental illnesses.

• Aibotics Inc.: This segment focuses on the application of artificial intelligence in the operation of robotic devices. Its primary product is the Philbot, an AI-powered massage robot.

Ehave, Inc. positions itself as an innovator that supplements, rather than replaces, existing care models. Its key competitive advantage is its approach to cognitive assessment, which utilizes established, clinically proven methods rather than creating new ones, potentially lowering the barrier to clinical adoption. While facing competition from large general Electronic Health Record (EHR) systems like Epic and Allscripts, Ehave differentiates itself by providing specialized focus areas, such as at-home ketamine infusion therapy via Ketadash, which is highly differentiated from clinic-based competitors. Additionally, the company’s focus on data richness, user engagement, and multi-screen deployment gives it a distinct edge in the digital therapeutics market.

Ehave, Inc. serves a broad spectrum of clients across the healthcare ecosystem. Its target customers include medical practitioners, research institutions, pharmaceutical companies, and health insurance payors. The company has established key partnerships with recognized industry leaders, including MHS, a leading provider of psychological assessment tools, and Toronto’s Hospital for Sick Children, which has been crucial in the development and testing of its clinical tools. The overall customer base is intended to be patients and individuals requiring advanced mental health care.